Results on islet cell transplants

In May, James Shapiro linkurl:wrote in our pages;http://www.the-scientist.com/article/display/23394/ about progress using the Edmonton Protocol to transplant islet cells into patients with type 1 diabetes. In this week?s New England Journal of Medicine, he and a number of colleagues around the world linkurl:report the results;http://content.nejm.org/cgi/content/full/355/13/1318 of a phase 1-2 trial of the protocol in 36 patients. The findings were consistent which previous studies that Shapiro d

Written byIvan Oransky
| 2 min read

Register for free to listen to this article
Listen with Speechify
0:00
2:00
Share
In May, James Shapiro linkurl:wrote in our pages;http://www.the-scientist.com/article/display/23394/ about progress using the Edmonton Protocol to transplant islet cells into patients with type 1 diabetes. In this week?s New England Journal of Medicine, he and a number of colleagues around the world linkurl:report the results;http://content.nejm.org/cgi/content/full/355/13/1318 of a phase 1-2 trial of the protocol in 36 patients. The findings were consistent which previous studies that Shapiro discussed in his May piece: 16 patients (44%) met the primary endpoint of insulin independence with adequate glycemic control one year after their final transplant, five of whom remained insulin-independent at 2 years. In the entire group, 10 had partial function, 10 had complete graft loss, and 21 were able to attain insulin independence with good glycemic control at any point throughout the trial. Of these 21 subjects, 16 required insulin again at 2 years. The results ?confirmed that islet transplantation may successfully restore long-term endogenous insulin production and glycemic stability in subjects who have type 1 diabetes mellitus with unstable baseline control,? the authors conclude. ?However, normal endocrine reserve is rarely achieved, and insulin independence is gradually lost in most cases over time.? ?Therefore, islet transplantation may best be considered as an evolving therapy for use in highly selected patients with severe hypoglycemia or labile type 1 diabetes mellitus, provided all other attempts to stabilize glycemic control have been exhausted,? they write. A linkurl:guardedly optimistic editorial;http://content.nejm.org/cgi/content/full/355/13/1372; accompanying the study sounds similar notes: ?It is clear that poor long-term results, high costs, and the relatively high incidence of major and minor serious adverse events make it difficult to argue for expansion of islet transplantation to the general population,? Jonathan S. Bromberg and Derek LeRoith write. ?Nonetheless, the dramatic discoveries and successful dissemination of information in a relatively short period encourage us to believe these advances will continue apace."
Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member? Login Here

Meet the Author

Share
July Digest 2025
July 2025, Issue 1

What Causes an Earworm?

Memory-enhancing neural networks may also drive involuntary musical loops in the brain.

View this Issue
Screening 3D Brain Cell Cultures for Drug Discovery

Screening 3D Brain Cell Cultures for Drug Discovery

Explore synthetic DNA’s many applications in cancer research

Weaving the Fabric of Cancer Research with Synthetic DNA

Twist Bio 
Illustrated plasmids in bright fluorescent colors

Enhancing Elution of Plasmid DNA

cytiva logo
An illustration of green lentiviral particles.

Maximizing Lentivirus Recovery

cytiva logo

Products

The Scientist Placeholder Image

Sino Biological Sets New Industry Standard with ProPure Endotoxin-Free Proteins made in the USA

sartorius-logo

Introducing the iQue 5 HTS Platform: Empowering Scientists  with Unbeatable Speed and Flexibility for High Throughput Screening by Cytometry

parse_logo

Vanderbilt Selects Parse Biosciences GigaLab to Generate Atlas of Early Neutralizing Antibodies to Measles, Mumps, and Rubella

shiftbioscience

Shift Bioscience proposes improved ranking system for virtual cell models to accelerate gene target discovery